GGrantIndex
← Leaderboards

Stuart D Katz

Columbia University Health Sciences

Google Scholar ↗PubMed ↗ORCID ↗
$171,255,562
Attributed
$659,489,088
Total exposure
13
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $448.3M · FY2005–25
$500M$375M$250M$125M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$659,489,088 · 13

By mechanism

OT2$650,978,035 · 1
R01$5,529,292 · 3
K24$1,258,901 · 1
M01$950,292 · 5
R34$757,969 · 1
P41$14,599 · 2

Top collaborators

Most similar at Columbia University Health Sciences

Same institution · by research overlap

Others in their field

Top investigators on “Heart Failure”

Research focus

Heart FailureOxidative StressSerumNitric OxideHuman SubjectRegulationPhysiologicalCardiovascular SystemHuman Therapy EvaluationVascular EndotheliumRandomizedPathologic ProcessTissue /Cell CultureClinical TrialsClinical ResearchAntioxidantsPlethysmographyVasomotionBlood VesselsMediatingInsightMorbidity - Disease RateBiochemicalAmerican

Grant awards (46)

OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core$90,000
OT2 · FY2025 · HL · contact PI
OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core$109,438,442
OT2 · FY2024 · HL · contact PI
OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core$59,963,139
OT2 · FY2023 · HL · contact PI
OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core$33,203,136
OT2 · FY2022 · HL · contact PI
OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core$448,283,318
OT2 · FY2021 · HL · contact PI
CABG vs. PCI to Improve Outcomes in Systolic Heart Failure: A Pilot Feasibility Study - Resubmission - 1$378,955
R34 · FY2020 · HL · contact PI
CABG vs. PCI to Improve Outcomes in Systolic Heart Failure: A Pilot Feasibility Study - Resubmission - 1$379,014
R34 · FY2019 · HL · contact PI
Augmentation of Parasympathetic Signaling with Pyridostigmine in Heart Failure$301,648
R01 · FY2014 · HL · contact PI
Augmentation of Parasympathetic Signaling with Pyridostigmine in Heart Failure$733,473
R01 · FY2013 · HL · contact PI
Studies on Serial Phlebotomy in Voluntary Blood Donors$65,873
R01 · FY2013 · HL · contact PI
Augmentation of Parasympathetic Signaling with Pyridostigmine in Heart Failure$767,941
R01 · FY2012 · HL · contact PI
Augmentation of Parasympathetic Signaling with Pyridostigmine in Heart Failure$813,044
R01 · FY2011 · HL · contact PI
Studies on Serial Phlebotomy in Voluntary Blood Donors$381,375
R01 · FY2011 · HL · contact PI
Studies on Serial Phlebotomy in Voluntary Blood Donors$381,375
R01 · FY2010 · HL · contact PI
Studies on Serial Phlebotomy in Voluntary Blood Donors$381,375
R01 · FY2009 · HL · contact PI
Studies on Genetics in Heart Failure$166,965
K24 · FY2009 · HL · contact PI
Studies on Serial Phlebotomy in Voluntary Blood Donors$381,188
R01 · FY2008 · HL · contact PI
Studies on Genetics in Heart Failure$163,819
K24 · FY2008 · HL · contact PI
Studies on Genetics in Heart Failure$160,759
K24 · FY2007 · HL · contact PI
Studies on Genetics in Heart Failure$157,785
K24 · FY2006 · HL · contact PI
HEART RATE RECOVERY AFTER EXERCISE DYNAMICAL ANALYSIS$8,085
P41 · FY2006 · RR · contact PI
Studies on Genetics in Heart Failure$154,893
K24 · FY2005 · HL
STUDIES ON IRON STATUS IN BLOOD DONORS$37,050
M01 · FY2005 · RR
EFFECTS OF INTRAVENOUS IRON SUCROSE ON VASODILATION IN NORMAL SUBJECTS$8,380
M01 · FY2005 · RR
SLEEP LOSS EFFECT ON VASODILATION IN MEDICAL RESIDENTS$2,646
M01 · FY2005 · RR
STUDIES ON ENDOTHELIAL DYSFUNCTION IN HEART FAILURE$327,000
R01 · FY2004 · HL
Effect of Intravenous Iron Sucrose and Placebo on Vasodi$130,576
M01 · FY2004 · RR
HEART RATE RECOVERY AFTER EXERCISE DYNAMICAL ANALYSIS$6,514
P41 · FY2004 · RR
STUDIES ON ENDOTHELIAL DYSFUNCTION IN HEART FAILURE$327,000
R01 · FY2003 · HL
ENDOTHELIAL DYSFUNCTION IN HEART FAILURE$113,670
K24 · FY2003 · HL
STUDIES ON ENDOTHELIAL DYSFUNCTION IN HEART FAILURE$327,000
R01 · FY2002 · HL
SR MOXONIDINE FOR CONGESTIVE HEART FAILURE (MOXCON)$192,910
M01 · FY2002 · RR
NATRECOR VERSUS DOBUTAMINE THERAPY FOR HEART FAILURE$192,910
M01 · FY2002 · RR
ENDOTHELIAL DYSFUNCTION IN HEART FAILURE$113,670
K24 · FY2002 · HL
STUDIES ON ENDOTHELIAL DYSFUNCTION IN HEART FAILURE$341,000
R01 · FY2001 · HL
SR MOXONIDINE FOR CONGESTIVE HEART FAILURE (MOXCON)$192,910
M01 · FY2001 · RR
NATRECOR VERSUS DOBUTAMINE THERAPY FOR HEART FAILURE$192,910
M01 · FY2001 · RR
ENDOTHELIAL DYSFUNCTION IN HEART FAILURE$108,459
K24 · FY2001 · HL
ENDOTHELIAL DYSFUNCTION IN HEART FAILURE$5,211
K24 · FY2001 · HL
NATRECOR VERSUS DOBUTAMINE THERAPY FOR HEART FAILURE$0
M01 · FY2001 · RR
SR MOXONIDINE FOR CONGESTIVE HEART FAILURE (MOXCON)$0
M01 · FY2001 · RR
ENDOTHELIAL DYSFUNCTION IN HEART FAILURE$113,670
K24 · FY2000 · HL
SR MOXONIDINE FOR CONGESTIVE HEART FAILURE (MOXCON)$0
M01 · FY2000 · RR
SR MOXONIDINE FOR CONGESTIVE HEART FAILURE (MOXCON)$0
M01 · FY2000 · RR
NATRECOR VERSUS DOBUTAMINE THERAPY FOR HEART FAILURE$0
M01 · FY2000 · RR
NATRECOR VERSUS DOBUTAMINE THERAPY FOR HEART FAILURE$0
M01 · FY2000 · RR